ARMY, MARINE CORPS, NAVY, AIR FORCE

MULTISERVICE TACTICS, TECHNIQUES, AND PROCEDURES FOR TREATMENT OF CHEMICAL AGENT CASUALTIES AND CONVENTIONAL MILITARY CHEMICAL INJURIES

FM 4-02.285 (FM 8-285)
MCRP 4-11.1A
NTRP 4-02.22
AFTTP (I) 3-2.69

SEPTEMBER 2007

DISTRIBUTION RESTRICTION: Approved for public release; distribution is unlimited.
FOREWORD

This publication has been prepared under our direction for use by our respective commands and other commands as appropriate.

RUSSELL J. CZERW
Major General, US
Commander, US Army Medical
Department Center and School

JAMES F. AMOS
Lieutenant General, US Marine Corps
Deputy Commandant for Combat
Development and Integration

T. L. DAVIDSON
Captain, US Navy
Acting
Navy Warfare Development Command

THOMAS J. LOFTUS
Major General, USAF, MC, CFS
Assistant Surgeon General
Health Care Operations
Office of the Surgeon General
PREFACE

1. Purpose

This publication provides multiservice tactics, techniques, and procedures (MTTP) and is designed for use as a reference for trained members of the Armed Forces Medical Services and other medically qualified personnel on the recognition and treatment of chemical agent casualties and conventional military chemical injuries. Additionally, this field manual (FM) provides information on first aid (self-aid and buddy aid) and enhanced first aid (combat lifesaver [United States (US) Army]) for these casualties.

2. Scope

a. This publication classifies and describes chemical warfare (CW) agents and other hazardous chemicals associated with military operations and describes how to diagnose and treat conventional military chemical injuries (that is, riot control agents, smokes, incendiary agents, and other toxic industrial chemicals [TICs]). Further, this publication—

   (1) Describes procedures for recognizing chemical casualties (Appendix A).
   (2) Describes measures for handling contaminated clothing and equipment at medical treatment facilities (MTFs) (Appendix B).
   (3) Describes medical management and treatment in chemical operations (Appendix C).
   (4) Describes procedures for individual skin protection and decontamination (Appendix D).
   (5) Describes procedures for administering nerve agent antidotes (Appendix E).
   (6) Provides an immediate/emergency treatment ready reference for the treatment of CW agents and some TICs (Appendix F).

b. Unless this publication states otherwise, masculine nouns and pronouns do not refer exclusively to men.

c. The use of trade names or trademarks in this publication is for illustrative purposes only. Their use does not constitute endorsement by the Department of Defense (DOD).

d. Metric measurements used throughout this publication are approximate equivalents of the customary units of measure. They are provided for the convenience of the users of this publication.

3. Applicability

a. This publication applies to the Active Army, the Army National Guard/Army National Guard of the United States, and the United States Army Reserve unless otherwise stated.

b. The audience for this publication is the trained members of the Armed Forces Medical Services and other medically qualified personnel. This publication is in consonance with the following North Atlantic Treaty Organization (NATO) International Standardization Agreements (STANAGs); American, British, Canadian, and Australian (ABCA) Quadripartite Standardization Agreements (QSTAGs); and Quadripartite Advisory Publication (QAP) 256.
When amendment, revision, or cancellation of this publication is proposed which will affect
or violate the international agreements concerned, the preparing agency will take
appropriate reconciliatory action through international standardization channels.

c. The Army Medical Department (AMEDD) is in a transitional phase with regards to
certain terminology. This publication uses the most current terminology; however, other
MTTP-series and Army FM 4-02-series and FM 8-series may use the older terminology.
Changes in terminology are a result of adopting the terminology currently used in the joint
and/or NATO and ABCA Armies publication arenas. The following terms are synonymous
and the current terms are listed first:

1. Medical logistics (MEDLOG), health service logistics (HSL), and combat health
   logistics (CHL).

2. Roles of care, levels of care, and echelons of care which is a NATO term.

3. Chemical, biological, radiological and nuclear (CBRN), chemical, biological,
   radiological, nuclear, and high yield explosives (CBRNE), and nuclear, biological and
   chemical (NBC).

4. Implementation Plan

   Participating Service command offices of primary responsibility (OPRs) will review this
publication, validate the information and, where appropriate, reference and incorporate it in
Service manuals, regulations, and curricula as follows:

   **Army.** The Army will incorporate this publication into the US Army Doctrine and
   Training Literature Program as directed by the Commander, US Army Training and Doctrine
   Command (TRADOC). Distribution is in accordance with applicable directives and the Initial
   Distribution Number (IDN) 115861, requirements for FM 4-02.285, as listed on the
   authentication page.

   **Marine Corps.** The Marine Corps will incorporate the procedures in this publication in
   US Marine Corps (USMC) training and doctrine publications as directed by the Commanding
   General, US Marine Corps Combat Development Command (MCCDC). Distribution is in
   accordance with the Marine Corps Publication Distribution System (MCPDS).

   **Navy.** The Navy will incorporate these procedures in US Navy (USN) training and
doctrine publications as directed by the Commander, Navy Warfare Development Command
(NWDC)(N5). Distribution is in accordance with Military Standard Requisitioning and Issue

---

*Marine Corps PCN: 144 000129 00*
**Air Force.** The Air Force will validate and incorporate appropriate procedures in this publication in accordance with applicable governing directives. Distribution is in accordance with Air Force Instruction (AFI) 33-360.

5. **User Information**

   a. The proponent of this publication is the US AMEDD Center and School (USAMEDDC&S). The USAMEDDC&S developed this publication with the joint participation of the approving Service commands.

   b. We encourage change recommendations for the purpose of improving this publication. Key your comments to the specific page and paragraph and provide a rationale for each recommendation. Send comments and recommendations directly to—

<table>
<thead>
<tr>
<th>Army</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commander</td>
</tr>
<tr>
<td>US Army Medical Department Center and School</td>
</tr>
<tr>
<td>ATTN: MCCS-FCD-L</td>
</tr>
<tr>
<td>1400 East Grayson Street</td>
</tr>
<tr>
<td>Fort Sam Houston, TX 78234-5052</td>
</tr>
<tr>
<td>DSN 471-9866/9531 COMM (210) 221-9866/9531</td>
</tr>
<tr>
<td>e-mail: <a href="mailto:medicaldoctrine@amedd.army.mil">medicaldoctrine@amedd.army.mil</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th><em>Marine Corps</em></th>
</tr>
</thead>
<tbody>
<tr>
<td>Commanding General</td>
</tr>
<tr>
<td>US Marine Corps Combat Development Command</td>
</tr>
<tr>
<td>ATTN: C42 (Director)</td>
</tr>
<tr>
<td>3300 Russell Road</td>
</tr>
<tr>
<td>Quantico, VA 22134-5001</td>
</tr>
<tr>
<td>DSN 278-6234 COMM (703) 784-6234</td>
</tr>
<tr>
<td>Web site: <a href="https://www.doctrine.usmc.mil">https://www.doctrine.usmc.mil</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Navy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commander</td>
</tr>
<tr>
<td>Navy Warfare Development Command</td>
</tr>
<tr>
<td>ATTN: N5</td>
</tr>
<tr>
<td>686 Cushing Road</td>
</tr>
<tr>
<td>Newport, RI 02841-1207</td>
</tr>
<tr>
<td>DSN 948-1070/4201 COMM (401) 841-1070/4201</td>
</tr>
<tr>
<td>e-mail: <a href="mailto:alsapubs@nwdc.navy.mil">alsapubs@nwdc.navy.mil</a></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Air Force</th>
</tr>
</thead>
<tbody>
<tr>
<td>Commander</td>
</tr>
<tr>
<td>Air Force Doctrine Center</td>
</tr>
<tr>
<td>ATTN: DR</td>
</tr>
<tr>
<td>155 North Twining Street</td>
</tr>
<tr>
<td>Maxwell AFB, AL 36112-6112</td>
</tr>
<tr>
<td>DSN 493-5645 COMM (334) 953-5645</td>
</tr>
<tr>
<td>e-mail: <a href="mailto:afdc.dr2@maxwell.af.mil">afdc.dr2@maxwell.af.mil</a></td>
</tr>
</tbody>
</table>

*Marine Corps.* Readers of this publication are encouraged to submit suggestions and changes through the Universal Need Statement (UNS) process. The UNS submission process is delineated in Marine Corps Order 3900.15A, Marine Corps Expeditionary Force Development System, which can be obtained from the Marine Corps Publications Electronic Library Online (universal reference locator: [http://www.usmc/directlv.nsf/web+orders](http://www.usmc/directlv.nsf/web+orders)). The UNS recommendation should include the following information:

- Location of change (publication number and title; current page number; paragraph number (if applicable), line number; figure or table number (if applicable).
- Nature of change (addition/deletion of text; proposed new text).
# MULTISERVICE TACTICS, TECHNIQUES AND PROCEDURES
## FOR
### TREATMENT OF CHEMICAL AGENT CASUALTIES AND CONVENTIONAL MILITARY CHEMICAL INJURIES

## TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>EXECUTIVE SUMMARY</td>
<td>xiii</td>
</tr>
<tr>
<td>CHAPTER I CHEMICAL WARFARE AGENT CASUALTIES</td>
<td>I-1</td>
</tr>
<tr>
<td>The Threat of Chemical Warfare Agents to United States</td>
<td>I-1</td>
</tr>
<tr>
<td>Military Employment of Chemical Warfare Agents</td>
<td>I-2</td>
</tr>
<tr>
<td>Routes of Entry</td>
<td>I-2</td>
</tr>
<tr>
<td>Classification of Chemical Warfare Agents</td>
<td>I-2</td>
</tr>
<tr>
<td>Means of Delivery of Chemical Warfare Agents</td>
<td>I-3</td>
</tr>
<tr>
<td>Diagnosis of Injury from Chemical Warfare Agents</td>
<td>I-4</td>
</tr>
<tr>
<td>Protective Measures and Handling of Chemical Warfare Agent Casualties</td>
<td>I-4</td>
</tr>
<tr>
<td>Chemical Warfare Agent Contamination Detection and Identification</td>
<td>I-5</td>
</tr>
<tr>
<td>Medical Management</td>
<td>I-6</td>
</tr>
</tbody>
</table>

*This publication supersedes FM 8-285/NAVMED P-5041/AFJMAN 44-149/FMFM 11-11, 22 December 1995

**DISTRIBUTION RESTRICTION:** Approved for public release; distribution is unlimited
Personal Decontamination................................. I-6
Casualty Decontamination............................... I-6
First Aid.......................................................... I-6
Medical Treatment............................................ I-7
Medical Evacuation.......................................... I-7
Individual Prescriptions................................. I-7
Medical Surveillance........................................ I-8

CHAPTER II
LUNG-DAMAGING AGENTS (CHOKING AGENTS) .......... II-1
General ......................................................... II-1
Central Pulmonary Agents.............................. II-1
Peripheral Pulmonary Agents......................... II-2
Properties of Phosgene ..................................... II-4

CHAPTER III
NERVE AGENTS .................................................. III-1
General .......................................................... III-1
Physical and Chemical Properties.................... III-1
Absorption of and Protection Against Nerve Agents III-2
Effects of Nerve Agents ..................................... III-2
Clinical Presentation and Diagnosis of Nerve Agent
Poisoning........................................................ III-10
Prevention and Treatment of Nerve Agent Poisoning III-11
Prevention of Poisoning...................................... III-12
Effects of Nerve Agent Antidotes...................... III-12
Rate of Absorption .......................................... III-13
Symptoms Produced by Antidotes..................... III-13
Elements of Self-Aid and Buddy Aid.................. III-15
The Nerve Agent Antidote Kit, MARK I.............. III-16
Antidote Treatment, Nerve Agent, Autoinjector........ III-17
Convulsant, Antidote for Nerve Agent, Autoinjector III-18
Principles for the Use of the MARK I and Antidote
Treatment Nerve Agent Autoinjector................. III-19
Principles for the Use of Convulsant, Antidote for Nerve
Agent............................................................ III-20
Treatment in a Medical Treatment Facility............. III-21
Administration of Follow-on Medical Treatment...... III-22
Medical Aerosolized Nerve Agent Antidote............ III-23
Nerve Agent Pyridostigmine Bromide Pretreatment for
Soman Nerve Agent Poisoning......................... III-24
The Soman Nerve Agent Pyridostigmine Bromide
Pretreatment Tablet Set.................................. III-25
Effects of Pyridostigmine Bromide ..................... III-27
Principles for the Use of Pyridostigmine Bromide..... III-27
Administration of Pyridostigmine Bromide Pretreatment in
an Uncontaminated Environment...................... III-28
Signs and Symptoms of Pyridostigmine Bromide Overdose, Adverse Reactions, and Contraindications..............................III-28
Emergency Medical Treatment for Pyridostigmine Bromide Adverse Side Effects, Allergic Reactions, and Overdose……..III-29

CHAPTER IV  
CYANOCGEN BLOOD AGENTS .............................................IV-1
General .............................................................................................IV-1
Protection..........................................................................................IV-1
Pathology..........................................................................................IV-2
Symptoms.........................................................................................IV-2
Diagnosis..........................................................................................IV-3
Prognosis..........................................................................................IV-3
Self-Aid .............................................................................................IV-3
Buddy Aid .........................................................................................IV-4
Treatment .........................................................................................IV-4

CHAPTER V  
BLISTER AGENTS (VESICANTS)............................................V-1
General ..............................................................................................V-1
Self-Aid ..............................................................................................V-2
Precautions for Receiving Casualties................................................V-2
Protection...........................................................................................V-2
Sulfur Mustard ...................................................................................V-2
Effects of Sulfur Mustard on the Eyes ...............................................V-3
Effects of Sulfur Mustard on the Skin ................................................V-4
Effects of Sulfur Mustard on the Respiratory Tract............................V-7
Systemic and Gastrointestinal Effects of Sulfur Mustard .................V-8
Nitrogen Mustards .............................................................................V-10
Arsenical Vesicants ...........................................................................V-10
Effects of Arsenical Vesicants on the Eyes .....................................V-11
Effects of Arsenical Vesicants on the Skin ......................................V-11
Effects of Arsenical Vesicants on the Respiratory Tract .................V-12
Systemic Effects of Arsenical Vesicants ........................................V-13
Phosgene Oximes .............................................................................V-13

CHAPTER VI  
INCAPACITATING AGENTS .......................................................VI-1
General .............................................................................................VI-1
Diagnosis ..........................................................................................VI-2
Protection, Decontamination, and First Aid ......................................VI-4

CHAPTER VII  
RIOT CONTROL AGENTS (IRRITANT AGENTS AND VOMITING AGENTS)........................................VII-1
Irritant Agents ..................................................................................VII-1
Protection..........................................................................................VII-1
Properties ........................................................................................VII-2
Effects .............................................................................................VII-2
Diagnosis ..........................................................................................VII-3
Self-Aid ............................................................................................VII-3
CHAPTER VIII
SMOKES ................................................................. VIII-1
General ......................................................................... VIII-1
Protection Against Smokes ........................................ VIII-2
Petroleum Oil Smokes .................................................. VIII-2
Zinc Oxide Mixtures ...................................................... VIII-2
Sulfur Trioxide-Chlorsulfonic Acid ................................ VIII-3
Titanium Tetrachloride ............................................... VIII-4
White Phosphorus Smoke ............................................. VIII-5
Red Phosphorus Smoke ............................................... VIII-5
Colored Smokes .......................................................... VIII-5

CHAPTER IX
INCENDIARY AGENTS ............................................ IX-1
Types of Incendiary Agents .......................................... IX-1
Thermite ........................................................................ IX-1
Magnesium and Its Alloys .......................................... IX-1
White Phosphorus ........................................................ IX-2
Combustible Hydrocarbon Incendiaries ...................... IX-3
Flame Weapon Attack ................................................ IX-3
Firebomb Attack ........................................................ IX-3

CHAPTER X
TOXIC INDUSTRIAL CHEMICALS ............................. X-1
General ........................................................................... X-1
Acids ............................................................................... X-2
Ammonia ........................................................................... X-3
Carbon Monoxide ........................................................ X-4
Chlorine ............................................................................ X-5
Ethylene Oxide .............................................................. X-6
Hydrogen Fluoride ......................................................... X-8
Hydrogen Sulfide .......................................................... X-9
Oxides of Nitrogen ......................................................... X-11
Inorganic Phosphorus Compounds ............................... X-12
Removal of Skin Exposure Reduction Paste Against Chemical Warfare Agents ........................................................... D-4
Detailed Procedures for Decontaminating the Eyes ........................................................... D-4
Detailed Procedures for Decontaminating the Skin (Hands, Face, Neck, Ears, and Other Exposed Areas) Using the M291 Skin Decontaminating Kit ........................................................... D-5
Reactive Skin Decontamination Lotion ...................................................................... D-7
Procedures for Decontaminating Individual Equipment Using the M295 Kit ........................................................................... D-8

APPENDIX E PROCEDURES FOR ADMINISTERING THE NERVE AGENT ANTIDOTES ........................................................................ E-1
Injection Site ...................................................................................... E-1
Self-Aid .............................................................................................. E-1

APPENDIX F CHEMICAL WARFARE AGENTS AND TOXIC INDUSTRIAL CHEMICALS IMMEDIATE/EMERGENCY TREATMENT READY REFERENCE ........................................................................ F-1

REFERENCES .......................................................................................... References-1
GLOSSARY .............................................................................................. Glossary-1
INDEX .................................................................................................... Index-1

FIGURES

Figure III-1. Autonomic Nervous System ........................................ III-5
Figure III-2. Pyridostigmine Bromide Tablet Cardboard Sleeve Labels ........................................................................... III-26
Figure III-3. Pyridostigmine Bromide Blister Pack Front and Back Label ........................................................................... III-26
Figure D-1. Skin Exposure Reduction Paste Against Chemical Warfare Agents Packet Front Label ........................................................... D-1
Figure D-2. Skin Exposure Reduction Paste Against Chemical Warfare Agents Packet Back Label ........................................................... D-2
Figure D-3. The M291 Skin Decontaminating Kit ........................................................... D-5
Figure D-4. The M295 Decontaminating Packet, Individual Equipment .............................................................................................. D-9
Figure E-1. Nerve Agent Antidotes ...................................................................... E-1
Figure E-2. Thigh Injection Site ................................................................ ...... E-3
Figure E-3. Buttocks Injection Site ................................................................... E-3
Figure E-4. Removing Atropine Autojector from Clip ........................................ E-3
Figure E-5. Self-Aid Thigh Injection ................................................................... E-4
Figure E-6. Self-Aid Buttocks Injection ............................................................ E-4
Figure E-7. Removing 2-PAM CI Autoinjector from Clip ....................................... E-4
Figure E-8. One Set of Used Autoinjectors Attached to Pocket Flap ....................... E-5
Figure E-9. Preparing ATNAA or CANA for Injection ........................................ E-5
Figure E-10. Used ATNAA Attached to Clothing..............................E-6
Figure E-11. Injecting the Casualty's Thigh......................................E-8
Figure E-12. Injecting the Casualty's Buttocks.................................E-9
Figure E-13. Three Sets of Used MARK I Autoinjectors and
One CANA Attached to Pocket Flap...........................................E-9
Figure E-14. Three Used ATNAA Autoinjectors and One
CANA Autoinjector Attached to Clothing.............................E-10

TABLES

Table I-1. Summary of Chemical Agent Effects............................... I-9
Table III-1. Signs and Symptoms of Nerve Agent Poisoning........... III-4
Table III-2. Time Course of Effects of Nerve Agents ....................... III-8
Table VI-1. Signs and Symptoms Produced by
Incapacitating Agents .................................................................VI-3
Table E-1. Self-Aid for Nerve Agent Poisoning..............................E-2
Table E-2. Buddy Aid/Combat Lifesaver Aid for Nerve
Agent Casualty ...........................................................................E-7
Table F-1. Emergency Treatment Ready Reference .....................F-1
EXECUTIVE SUMMARY
Multiservice Tactics, Techniques, and Procedures for Treatment of Chemical Agent Casualties and Conventional Military Chemical Injuries

Chapter I
Chemical Warfare Agent Casualties
Chapter I discusses the threat, military employment and classification of chemical warfare agents.

Chapter II
Lung-Damaging Agents (Choking Agents)
Chapter II discusses protection, pathology, symptoms, diagnosis and treatment of lung damaging agents.

Chapter III
Nerve Agents
Chapter III discusses effects, prevention, symptoms, diagnosis and treatment of nerve agents.

Chapter IV
Cyanogen Blood Agents
Chapter IV discusses protection, pathology, symptoms, diagnosis and treatment of cyanogen blood agents.

Chapter V
Blister Agents (Vesicants)
Chapter V discusses protection, properties, effects, symptoms and treatment of blister agents.

Chapter VI
Incapacitating Agents
Chapter VI discusses diagnosis, protection and treatment of incapacitating agents.
Chapter VII

Riot Control Agents (Irritant Agents and Vomiting Agents)
Chapter VII discusses protection, properties, effects, diagnosis and treatment of riot control agents.

Chapter VIII

Smokes
Chapter VIII discusses properties, pathology, symptoms, and treatment of different types of smokes.

Chapter IX

Incendiary Agents
Chapter IX discusses protection and treatment of different types of incendiary agents.

Chapter X

Toxic Industrial Chemicals
Chapter X discusses properties, pathology, symptoms, diagnosis and treatment of different types of toxic industrial chemicals.
PROGRAM PARTICIPANTS

The following commands and agencies participated in the development of this publication:

**Army**

United States Army Office of The Surgeon General, 5111 Leesburg Pike, Ste. 401, Falls Church, VA 22041-3258

United States Army Center for Health Promotion & Preventive Medicine, 5158 Blackhawk Road, Aberdeen Proving Ground, MD 21010-5403

United States Army Medical Research Institute of Infectious Diseases, 1425 Porter Street, Frederick, MD 21702-5011

United States Army Medical Research Institute of Chemical Defense, 3100 Ricketts Point Road, Aberdeen Proving Ground, MD 21010-5400

**Marine Corps**

United States Marine Corps Combat Development Command, ATTN: C42 (Director) 3300 Russell Road, Quantico, VA 22134-5001

**Navy**

United States Navy Warfare Development Command, ATTN: N5, 686 Cushing Road, Newport, RI 02841-1207

**Air Force**

Headquarters Air Force Doctrine Center, ATTN: DR, 155 North Twining Street, Maxwell AFB, AL 36112-6112
This page intentionally left blank.
Chapter I
CHEMICAL WARFARE AGENT CASUALTIES

Given the probability that a significant number of Gulf War veterans may have been exposed to low levels of sarin and cyclosarin during and after the war, and recent research findings indicating that low-level sarin exposures can result in chronic health sequelae, the Committee concludes that low-level exposure to chemical agents must be thoroughly investigated as a potential contributing cause of the multisymptom illnesses affecting Gulf War veterans, and that it is important that the precise mechanisms of chronic adverse effects of low-dose exposures be identified.

Research Advisory Committee on Gulf War Veterans’ Illnesses
2004 Report and Recommendations

It is believed that the use of chemical weapons dates back several centuries. However, the use of modern chemical weapons has its origins in World War I. Chemical gas (actually an aerosol or vapor) was used effectively on numerous occasions by both sides during this conflict to alter the outcome of battles. Chemical battlefield casualties were sustained. The Geneva Protocol, prohibiting use of chemical weapons in warfare, was subsequently proposed and signed in 1925. The United States, along with several other nations, signed with the stipulation that it will refrain only from the first use of chemical weapons, but reserves the right to retaliate in kind if chemical weapons were used against them (the United States did not ratify the Protocol until 1975).

1. The Threat of Chemical Warfare Agents to United States Forces
   a. Chemical warfare agents remain a significant and continuing HSS threat to US forces. Chemical weapons delivery may be accomplished through conventional or non-conventional means, causing extensive injury and contamination. Collateral damage to enemy storage facilities and/or destruction of their munitions by “friendly forces,” such as, bombs, artillery fire, or destruction of industrial facilities can release TICs. Traditionally, enemy commanders have regarded CW agents as a part of their conventional arsenal. The Chemical Weapons Convention (CWC), which banned the use of CW agents and was signed by 175 countries/states as of October 2005, will take many years to fully implement. The CWC was opened for signature on 13 January 1993. In accordance with Article XVIII of the CWC, the signature period ended on 28 April 1997, the day before the CWC entered into force. Countries/states that signed the CWC during this period (the “Signatory States”) must also ratify it through their standard national processes; countries/states that did not sign during this period, but now wish to become States Parties to the CWC, must accede to it. Not all countries have signed the CWC. In spite of the CWC and other diplomatic efforts, CW agents will be available to threat forces in regions where US forces may be deployed.

   b. Chemical warfare agents are readily obtainable. The ease of obtaining these weapons greatly increases the complexity and extent of the total threat. For example, nonmilitary organophosphate insecticide factories may also be used to produce nerve